Subjective Outcome
7 compoundsin Regimen’s catalog are configured to track libido via Rate Today. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
Libido in men is downstream of testosterone, dopaminergic signaling, and (less directly) growth hormone. The most robust evidence is for testosterone replacement: the T-Trials (Snyder et al., NEJM 2016) showed statistically significant improvements in sexual desire, sexual activity, and erectile function in men with confirmed hypogonadism over 12 months.
PT-141 (bremelanotide, a melanocortin receptor agonist) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is used off-label for men. The mechanism is central rather than vascular: it acts on melanocortin 4 receptors in the hypothalamus, separate from the testosterone axis. Kisspeptin, currently in clinical trials, modulates GnRH release and shows early signal in HSDD studies.
For women, the picture is more variable. Testosterone in women is used at much lower doses (typically 4–10 mg/week) and the trial evidence is thinner. PT-141 has the strongest regulatory dataset in this group.
Anchor citation: Snyder PJ et al.. Effects of Testosterone Treatment in Older Men (T-Trials). New England Journal of Medicine, 2016.
7 compounds
Bremelanotide
A melanocortin receptor agonist that enhances sexual desire and arousal in both men and women by acting centrally via the nervous system.
Tracks
Human Chorionic Gonadotropin
Glycoprotein hormone produced during pregnancy. Mimics luteinizing hormone (LH), stimulating Leydig cells in the testes to produce testosterone and maintain testicular volume. Commonly co-administered with TRT to preserve fertility and prevent testicular atrophy, or used as a post-cycle/restart bridge.
Tracks
Testosterone Ester (TRT)
Testosterone replacement therapy using a long-acting ester for stable hormone levels.
Tracks
Tracks
Tracks
Tracks
Pulsatile GnRH for HPG Axis Support
A synthetic decapeptide identical to native GnRH that triggers pituitary LH and FSH release, downstream stimulating endogenous testosterone and spermatogenesis. Used adjunctively in TRT to preserve testicular function and in hypogonadotropic hypogonadism via pulsatile dosing.
Tracks
In the T-Trials, sexual function improvements were measurable by month 3 and stable through month 12. The full response depends on starting testosterone level — men whose baseline total testosterone was lower had larger relative improvements. Sublingual and injection routes act faster than topical gels because they reach steady state in days rather than weeks.
No. PT-141 acts on the central melanocortin system, not the androgen axis. It produces an acute, dose-dependent effect lasting roughly 6–8 hours and is used on-demand rather than continuously. Men with confirmed hypogonadism typically need testosterone for sustained restoration; PT-141 can be added for acute responsiveness but does not address the underlying hormone deficit.
Regimen’s Rate Today scoring includes libido as a daily subjective dimension. The 30-day sparkline sits next to your testosterone or PT-141 dose log, so it’s easy to see whether the protocol is moving the dimension that prompted it. Apple Health can store testosterone lab readings if you enter them manually after your bloodwork.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes